Among black
kidney failure
patients undergoing dialysis, women are much less likely than men to want to receive
kidney transplants from living donors, despite more offers from family and friends.
Kenar D. Jhaveri, MD, and Richard Barnett, MD, Feinstein Institute for Medical Research scientists and Northwell Health Department of Internal Medicine nephrologists, published a Letter to the Editor in the New England Journal of Medicine, which profiles a novel drug combination with the potential to help prevent rejection of a donor
kidney in
transplant patients undergoing cancer treatment.
Among the 50 trials, 30 were primary prevention trials (general populations, smokers and workers exposed to asbestos,
patients with oesophageal dysplasia, male physicians,
patients with non-melanoma skin cancer, postmenopausal women,
patients undergoing chronic haemodialysis,
patients with end stage renal disease, ambulatory elderly women with vitamin D insufficiency,
patients with chronic renal failure, older people with femoral neck fractures,
patients with diabetes mellitus, elderly women with a low serum 25 - hydroxyvitamin D concentration, health professionals, people with a high fasting plasma total homocysteine concentration, or
kidney transplant recipients), and 20 were secondary prevention trials (
patients with cardiovascular disease, coronary heart disease, acute myocardial infarction, unstable angina, transient ischaemic attack, stroke, angiographically proved coronary atherosclerosis, vascular disease, or aortic valve stenosis).
Plasma PLP concentrations are also low in
patients receiving maintenance
kidney dialysis or intermittent peritoneal dialysis, as well as those who have
undergone a
kidney transplant, perhaps due to increased metabolic clearance of PLP.